Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
New Fortress Energy
NFE
5
Lantheus
LNTH
US OptionsDetailed Quotes
TSHA250516C1000
- 0.80
- 0.000.00%
15min DelayTrading Apr 23 11:11 ET
0.00High0.00Low
0.00Open0.80Pre Close0 Volume6 Open Interest1.00Strike Price0.00Turnover305.59%IV-0.28%PremiumMay 16, 2025Expiry Date0.81Intrinsic Value100Multiplier18DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8873Delta0.1561Gamma2.01Leverage Ratio-0.0066Theta0.0003Rho1.78Eff Leverage0.0008Vega
Taysha Gene Therapies Newsroom
Cantor Fitzgerald Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $7
JMP Securities Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $5
Needham Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $6
Needham Reiterates Buy on Taysha Gene Therapies, Maintains $6 Price Target
Top 10 Russell 2000 Weekly Gainers and Losers as Wall Street Crashes
Wells Fargo Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $7.5
Press Release: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Wells Fargo Reaffirms Their Buy Rating on Taysha Gene Therapies (TSHA)
12 Health Care Stocks Moving In Monday's Intraday Session
How Peter Marks' FDA Departure Is Impacting Pharma, Biotech Stocks
Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet
Express News | Taysha Gene Therapies Down 10.9%, Solid Biosciences Down 7.2%, US-Listed Shares of CRISPR Therapeutics Down 3.8%, Beam Therapeutics Down 3.2% Premarket
Express News | Shares of Gene Therapy Makers and Developers Fall Premarket After Report That FDA Official Peter Marks Has Resigned
Taysha Gene Therapies Up 18%, Insiders Still In The Red By US$427k
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Truist Financial Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating
A Quick Look at Today's Ratings for Taysha Gene Therapies(TSHA.US), With a Forecast Between $5 to $7.5
Taysha Gene Therapies Full Year 2024 Earnings: Beats Expectations
Taysha Gene Therapies Is Maintained at Buy by Chardan Capital
Taysha Gene Therapies Price Target Maintained With a $7.00/Share by Chardan Capital
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
